Navigation Links
PharmacoFore, Inc. Secures $10 Million in Equity Financing From Founders Fund
Date:12/27/2011

SAN CARLOS, Calif., Dec. 27, 2011 /PRNewswire/ -- PharmacoFore, Inc., a privately held biopharmaceutical company, today announced a $10 million round of equity financing from Founders Fund and the addition of Founders Fund partner Ken Howery to its Board of Directors.  

PharmacoFore uses innovative synthetic organic chemistry to create novel medicines for treating a variety of conditions related to the central and peripheral nervous systems.  One of its key platform technologies has generated a series of novel molecules that it believes will facilitate prevention of the abuse and misuse of prescription drugs -- now the leading cause of accidental death in the United States, surpassing auto-related fatalities. 

Wes Sterman, CEO of PharmacoFore, Inc., commented, "We are thrilled to have the enthusiastic support of Founders Fund as we advance our pipeline, along with partners, to regulatory approval and commercialization throughout the world." 

Ken Howery is a co-founder of PayPal and served as the company's first CFO prior to its initial public offering and subsequent sale to eBay.  Before launching Founders Fund, Ken Howery was a member of the research and trading teams at Clarium Capital Management.

Founders Fund investment philosophy is distinguished by its focus on innovative, cost-effective companies that can capture multi-billion dollar markets through transformational technologies that can lead to positive change in the world.

About Founders Fund
Founders Fund provides capital to transformational businesses run by world-class entrepreneurs. Companies the firm has backed include Facebook (managing partner Peter Thiel was Facebook's first outside backer), Quantcast, SpaceX, Palantir Technologies, RoboteX, Spotify, Yammer, Mint.com, and Slide. The firm, which pursues a founder-friendly investment strategy, is overseen by four managing partners, all of whom have founded companies worth more than $1 billion: Peter Thiel (PayPal); Ken Howery (PayPal); Luke Nosek (PayPal); and Sean Parker (Napster; Plaxo, Causes; founding president, Facebook).

About PharmacoFore, Inc.
PharmacoFore, Inc., is a privately held biopharmaceutical company focused on creating novel medicines that provide clear clinical benefits over existing drugs, enhance patient care, and prevent the misuse, abuse, and overdose of prescription medications.  

PharmacoFore, Inc. Contact:
A. Gregory Sturmer
VP, Finance and Chief Financial Officer
650-331-4010
gsturmer@pfore.com

Media Contact:
Tiberend Strategic Advisors, Inc.
212-827-0020
Jason Rando / Andrew Mielach
jrando@tiberend.com / amielach@tiberend.com

 


'/>"/>
SOURCE PharmacoFore, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmacoFore, Inc. Announces Positive Results from a Phase I Clinical Study of Its Hydromorphone Bio-Activated Molecular Delivery™ System, and Upcoming Presentation at the 2011 BIO Business Forum During the Annual BIO International Convention in Was
2. AuraSense Therapeutics Secures Series B Equity Investment
3. United Spinal Secures Leading Public Policy and Durable Medical Equipment Specialist: Alex Bennewith is New Director of Government Relations
4. ACT Secures First Patent for Generating Hemangioblast Cells to Treat a Broad Spectrum of Vascular and Hematopoietic Disorders
5. Awarepoint Corporation Secures $27 Million in New Financing: Kleiner Perkins Caufield & Byers Leads Round
6. NeurogesX, Inc. Secures $20 Million Debt Facility
7. Bacterin Secures $15 Million Credit Facility with MidCap Financial and Silicon Valley Bank
8. SurgiQuest, Inc. Secures $19 Million to Fund Commercialization and Launch the Next Generation Access Technology Cited by Surgeons as The Future of Minimally Invasive Surgery
9. Digital Assent Secures $7.5 Million Series B Funding
10. Precyse Secures Healthcare IT Executive Chris Powell as New President
11. Ethicon, Inc. Announces Availability of ETHICON SECURESTRAP™ 5mm Absorbable Strap Fixation Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
Breaking Medicine News(10 mins):